TauRx seeks UK MHRA approval for revolutionary Alzheimer's treatment

TauRx Pharmaceuticals has applied to the UK Medicines and Healthcare Products Regulatory Agency for approval of hydromethylthionine mesylate (HMTM) to treat Alzheimer's disease. The treatment targets mild cognitive impairment and mild to moderate dementia caused by Alzheimer's.

Commenting on the submission, Professor Claude Wischik, Executive Chairman of TauRx, said: “This is a significant milestone for TauRx and is an important step in potentially bringing a new type of treatment and a new hope to patients and families who carry the burden of this terrible disease.”

Previously, the UK regulator had assigned HMTM to the innovative licensing and access pathway. If approved, the UK could be the first country to provide this oral treatment.

The marketing application is supported by extensive evidence from the 24-month Phase III LUCIDITY clinical trial and two earlier Phase III studies, all showing HMTM's effectiveness in slowing cognitive decline, preserving daily functioning, and reducing brain atrophy.